Shin Nippon Biomedical Laboratories Overview
- Year Founded
-
1957
- Status
-
Public
- Employees
-
994
- Stock Symbol
-
2395
- Investments
-
21
- Share Price
-
$6.96
- (As of Friday Closing)
Shin Nippon Biomedical Laboratories General Information
Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company's segment includes: CRO business (non-clinical business and clinical business), translational research business, Medipolis business, U.S. real estate business, and other businesses. The CRO business segment derives maximum revenue.
Contact Information
Website
www.snbl.comCorporate Office
- 8-1 Akashi-cho, Chuo-ku
- Saint Luke's Tower, 28th floor
- Kagoshima, Kagoshima 104-0044
- Japan
Corporate Office
- 8-1 Akashi-cho, Chuo-ku
- Saint Luke's Tower, 28th floor
- Kagoshima, Kagoshima 104-0044
- Japan
Shin Nippon Biomedical Laboratories Stock Performance
As of 20-Nov-2026, Shin Nippon Biomedical Laboratories’s stock price is $6.96. Its current market cap is $290M with 41.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.96 | $7.20 | $6.67 - $12.87 | $290M | 41.6M | 308K | $0.87 |
Shin Nippon Biomedical Laboratories Financials Summary
As of 30-Sep-2026, Shin Nippon Biomedical Laboratories has a trailing 12-month revenue of $224M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 501,775 | 533,795 | 559,387 | 508,028 |
| Revenue | 224,460 | 215,790 | 212,552 | 183,061 |
| EBITDA | 73,239 | 64,587 | 57,245 | 60,867 |
| Net Income | 36,240 | 30,298 | 32,294 | 38,281 |
| Total Assets | 694,747 | 657,180 | 617,583 | 504,145 |
| Total Debt | 310,066 | 258,099 | 230,376 | 173,022 |
Shin Nippon Biomedical Laboratories Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Shin Nippon Biomedical Laboratories Comparisons
Industry
Financing
Details
Shin Nippon Biomedical Laboratories Competitors (37)
One of Shin Nippon Biomedical Laboratories’s 37 competitors is CMIC CMO, a Private Equity-Backed company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CMIC CMO | Private Equity-Backed | Tokyo, Japan | ||||
| Shionogi | Corporation | Osaka, Japan | ||||
| Evotec | Formerly PE-Backed | Hamburg, Germany | ||||
| Ipsen | Formerly PE-Backed | Paris, France | ||||
| Vimta Labs | Corporation | Hyderabad, India |
Shin Nippon Biomedical Laboratories Patents
Shin Nippon Biomedical Laboratories Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026164060-A1 | Marker for cancer originating in pancreatic duct or precancerous lesion thereof | Pending | 28-Jan-2025 | ||
| WO-2026126716-A1 | Administration device | Pending | 11-Dec-2024 | ||
| JP-2025041218-A | Biomarker comprising limch1 | Pending | 13-Sep-2023 | ||
| JP-2026521371-A | Composition for improving mucosal penetration | Pending | 31-May-2023 | ||
| AU-2024282997-A1 | Compositions for enhanced mucosal penetration | Pending | 31-May-2023 | A61K9/0043 |
Shin Nippon Biomedical Laboratories Signals
Shin Nippon Biomedical Laboratories Investments & Acquisitions (21)
Shin Nippon Biomedical Laboratories’s most recent deal was a Later Stage VC with Cardio Intelligence for . The deal was made on 09-Mar-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cardio Intelligence | 09-Mar-2026 | Later Stage VC | Diagnostic Equipment | ||
| Hearvana | 05-Nov-2025 | Seed Round | Software Development Applications | ||
| Tasso-SNBL | 27-Mar-2025 | Joint Venture | Distributors/Wholesale | ||
| Kolmar BioTech | 05-Dec-2024 | PIPE | Biotechnology | ||
| Shizen Connect | 29-Nov-2024 | Seed Round | Business/Productivity Software |
Shin Nippon Biomedical Laboratories ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
19.61 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Shin Nippon Biomedical Laboratories Exits (4)
Shin Nippon Biomedical Laboratories’s most recent exit was on 19-Aug-2021 from Life Log Technology. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Life Log Technology | 19-Aug-2021 | Completed |
|
||
| WaVe Life Sciences | 02-Feb-2015 | Completed |
|
||
| Agrivida | 09-Nov-2006 | Completed |
|
||
| WaVe Life Sciences | Corporate | Completed |
Shin Nippon Biomedical Laboratories Affiliates
Subsidiaries (8)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Tasso-SNBL | Japan | 2025 | |
| Gemseki | Tokyo, Japan | 2017 | |
| Trunk Solution | Bunkyo-ku, Japan | 2016 | |
| Satsuma Pharmaceuticals | Durham, NC | 2016 | |
| PPD SNBL | Tokyo, Japan | 2015 |
Shin Nippon Biomedical Laboratories FAQs
-
When was Shin Nippon Biomedical Laboratories founded?
Shin Nippon Biomedical Laboratories was founded in 1957.
-
Where is Shin Nippon Biomedical Laboratories headquartered?
Shin Nippon Biomedical Laboratories is headquartered in Kagoshima, Japan.
-
What is the size of Shin Nippon Biomedical Laboratories?
Shin Nippon Biomedical Laboratories has 994 total employees.
-
What industry is Shin Nippon Biomedical Laboratories in?
Shin Nippon Biomedical Laboratories’s primary industry is Drug Discovery.
-
Is Shin Nippon Biomedical Laboratories a private or public company?
Shin Nippon Biomedical Laboratories is a Public company.
-
What is Shin Nippon Biomedical Laboratories’s stock symbol?
The ticker symbol for Shin Nippon Biomedical Laboratories is 2395.
-
What is the current stock price of Shin Nippon Biomedical Laboratories?
As of 20-Nov-2026 the stock price of Shin Nippon Biomedical Laboratories is $6.96.
-
What is the current market cap of Shin Nippon Biomedical Laboratories?
The current market capitalization of Shin Nippon Biomedical Laboratories is $290M.
-
What is Shin Nippon Biomedical Laboratories’s current revenue?
The trailing twelve month revenue for Shin Nippon Biomedical Laboratories is $224M.
-
Who are Shin Nippon Biomedical Laboratories’s competitors?
CMIC CMO, Shionogi, Evotec, Ipsen, and Vimta Labs are some of the 37 competitors of Shin Nippon Biomedical Laboratories.
-
What is Shin Nippon Biomedical Laboratories’s annual earnings per share (EPS)?
Shin Nippon Biomedical Laboratories’s EPS for 12 months was $0.87.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process